GLP‐1 Receptor Agonists in Metabolic Dysfunction‐Associated Steatotic Liver Disease: Bridging Hepatic and Cardiovascular Outcomes
Open Access
- 24 March 2026
- journal article
- review article
- Published by Wiley in Chronic Diseases and Translational Medicine
- Vol. 12 (2) , 85-99
Abstract
Metabolic dysfunction‐associated steatotic liver disease (MASLD) affects over 30% of adults worldwide and represents a systemic cardiometabolic disorder in which cardiovascular disease is the leading cause of death. Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are uniquely positioned to address this liver–heart axis by combining hepatic disease‐modifying signals with proven cardiovascular risk reduction. This review synthesizes mechanistic, randomized trial, real‐world, and cardiovascular outcome evidence for GLP‐1RAs in MASLD and metabolic dysfunction‐associated steatohepatitis (MASH). In biopsy‐based trials, liraglutide (LEAN) increased steatohepatitis resolution without fibrosis worsening (39% vs. 9% with placebo), while semaglutide demonstrated dose‐dependent resolution (up to 59% vs. 17% in Phase 2). More recently, semaglutide 2.4 mg weekly met both histologic endpoints at interim analysis in F2–F3 MASH (resolution without fibrosis worsening 62.9% vs. 34.3%; fibrosis improvement ≥ 1 stage 36.8% vs. 22.4%), and tirzepatide (SYNERGY‐NASH) achieved high rates of MASH resolution (44%–62% vs. 10%) with concomitant fibrosis improvement signals (up to 51% vs. 30%). Cardiovascular outcome trials demonstrate consistent reductions in major adverse cardiovascular events with GLP‐1RAs, including liraglutide (LEADER), semaglutide (SUSTAIN‐6 and SELECT), and dulaglutide (REWIND). Mechanistically, GLP‐1RAs reduce hepatic lipogenesis and lipotoxicity, attenuate inflammation, improve insulin sensitivity, and modulate gut–brain–liver signaling, with systemic benefits on weight, blood pressure, and atherogenic lipoproteins. Collectively, the evidence supports GLP‐1RAs, particularly semaglutide and tirzepatide, as foundational therapies for MASLD patients with obesity, type 2 diabetes, advanced fibrosis, or heart failure phenotypes. Key gaps include treatment duration, durability of fibrosis benefit, and effectiveness in cirrhosis, requiring long‐term follow‐up.Keywords
This publication has 65 references indexed in Scilit:
- Comparative Effectiveness of Bariatric Surgery Versus GLP‐1 Receptor Agonists in Reducing the Risk of New‐Onset of NASH: A Retrospective Multinational Cohort Study From North America and EuropeEndocrinology, Diabetes & Metabolism, 2025
- The Rising Global Burden of MASLD and Other Metabolic Diseases (2000–2021)United European Gastroenterology Journal, 2025
- GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver DiseaseJAMA Internal Medicine, 2024
- Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials: a meta-epidemiological studyCochrane Database of Systematic Reviews, 2024
- Emulation of Randomized Clinical Trials With Nonrandomized Database AnalysesJAMA, 2023
- When Can Nonrandomized Studies Support Valid Inference Regarding Effectiveness or Safety of New Medical Treatments?Clinical Pharmacology & Therapeutics, 2021
- Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)Diabetologia, 2020
- Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetesDiabetes/Metabolism Research and Reviews, 2020
- New insights into the role and mechanism of c‐Jun‐N‐terminal kinase signaling in the pathobiology of liver diseasesHepatology, 2017
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver DiseasesHepatology, 2017